Mirae Asset Global Investments
EIGR

Mirae Asset Global Investments’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Mirae Asset Global Investments’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-511
Closed -$115K – 2624
2022
Q3 		$115K Buy
511
+176
+53% +$43.3K ﹤0.01% 2472
2022
Q2 		$63K Buy
+335
New +$67.5K ﹤0.01% 2366

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Mirae Asset Global Investments's EIGR Position: Q4 2022 in Review

Mirae Asset Global Investments sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 511 shares — an estimated $115K sold.

Mirae Asset Global Investments first reported a position in EIGR in Q2 2022 and held it in 2 quarters. The position peaked at $115K in Q3 2022. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

  • Mirae Asset Global Investments reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Mirae Asset Global Investments sold 511 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $115K.
  • Mirae Asset Global Investments first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2022 and held it in 2 quarters.
  • Mirae Asset Global Investments's Eiger BioPharmaceuticals, Inc. position peaked at $115K in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Mirae Asset Global Investments's 13F filing for Q4 2022, filed 9 Feb 2023.